China drugmaker begins trial production of AstraZeneca COVID-19 vaccine
SHENZHEN -- A Shenzhen-based drugmaker on Tuesday began trial production of a COVID-19 vaccine from multinational pharmaceutical company AstraZeneca.
Shenzhen Kangtai Biological Products Co. Ltd. announced that it has built a production workshop for the adenovirus vector vaccine developed by AstraZeneca and the University of Oxford, which won the approval for emergency use in the United Kingdom on Dec. 30.
The facility, with a floor area of 2,200 square meters, has an annual production capacity of 400 million doses.
The Shenzhen drugmaker signed a deal with AstraZeneca in August 2020 to introduce the latter's COVID-19 vaccine into China for which it is seeking clinical registration.
The company itself developed an inactivated coronavirus vaccine and is planning to launch phase 3 trials.
- 5.4-magnitude quake hits waters off China's Taiwan region: CENC
- Shanghai offers 'first cup of coffee' to May Day arrivals at airports
- China predicts over 344m inter-regional trips on first day of holiday
- Enjoy the May Day holiday
- Authorities warn of heavy rain, flood risks during holiday
- China launches immersive aerospace science center for kids, teenagers in Beijing
